Written by Private MD Labs Medical Writing Team • Last Updated: September 8, 2025
Thrombotic events, such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke, occur when blood clots form inappropriately within blood vessels. While these conditions are typically diagnosed through imaging studies and clinical assessment, blood tests play a crucial role in monitoring treatment effectiveness and assessing ongoing risk factors.
This specialized test measures levels of 11-dehydrothromboxane B2, a metabolite that indicates thromboxane production in the body. Thromboxane is a substance that promotes blood clotting and platelet aggregation. When levels remain high despite aspirin therapy, it suggests the medication may not be adequately suppressing clot formation, indicating an increased risk of thrombotic events. The test includes creatinine measurement to ensure accurate interpretation of results based on kidney function.
Although blood tests cannot directly diagnose thrombotic events themselves, they are fundamental for evaluating the effectiveness of preventive treatments like aspirin therapy. Many patients take aspirin to reduce their risk of blood clots, but individual responses to this medication can vary significantly. Testing helps ensure that antiplatelet therapy is working optimally to prevent future thrombotic complications.
Elevated 11-dhTXB2 levels while taking aspirin may indicate aspirin resistance or inadequate dosing, potentially requiring adjustment of antiplatelet therapy or additional preventive measures. This information helps healthcare providers optimize treatment strategies to reduce the risk of future thrombotic events.
The information here is for educational purposes only and is not a substitute for professional medical advice. Always consult with a healthcare provider for diagnosis, treatment, and management of thrombotic risk factors.